Drug Trial Radar · NCT03744910
Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients
Last checked: Nov 20, 2026Latest source record: Jul 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
194
Actual
Start
Oct 14, 2019
Primary completion
Apr 8, 2024
Study completion Apr 8, 2024
Sponsor
- Lead sponsor
- CSL BehringIndustry
- Sponsor type
- Industry
- Collaborators
- ICON Clinical Research
- First posted
- Nov 19, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial investigates the efficacy and safety of clazakizumab \[an anti-interleukin (IL)-6 monoclonal antibody (mAb)\] for the treatment of CABMR in recipients of a kidney transplant.
Conditions
- Antibody-mediated Rejection
Interventions
ClazakizumabBiological
Clazakizumab is a genetically engineered humanized immunoglobulin G1 (IgG1) mAb that binds to human IL-6
Physiologic saline solutionDrug
Normal saline
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline to Week 52 in Estimated Glomerular Filtration Rate (eGFR)Time frame: From Baseline to Week 52
- Number of Participants With Composite All-cause Allograft Loss or Irreversible Loss of Allograft FunctionTime frame: From Baseline to 4 years
- Percentage of Participants With Composite All-cause Allograft Loss or Irreversible Loss of Allograft FunctionTime frame: From Baseline to 4 years
- Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious TEAEs, and Adverse Events of Special Interest (AESIs)Time frame: Up to 4 years
- Percentage of Participants With TEAEs, Serious TEAEs, and AESIsTime frame: Up to 4 years
- Number of Participants Who Tested Positive for Polyoma BK Virus (BKV), Cytomegalovirus (CMV) and Epstein-Barr Virus (EBV)Time frame: From baseline up to 4 years
- Number of Participants With Abnormal Laboratory Test ResultsTime frame: Up to 4 years
- Percentage of Participants With Abnormal Laboratory Test ResultsTime frame: Up to 4 years
- Number of Participants With Clinically Significant Change in Vital Signs, Electrocardiograms (ECGs), and Physical ExaminationTime frame: Up to 4 years
- Number of Participants With Positive Anti-drug AntibodiesTime frame: Baseline, Weeks 12, 24, and 48
- Percentage of Participants With Positive Anti-drug AntibodiesTime frame: Baseline, Weeks 12, 24, and 48
Locations
142 sites in 15 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham (UAB) - University of Alabama Hospital (UAB Hospital)
Birmingham, Alabama
Mayo Clinic Hospital
Phoenix, Arizona
Keck Medical Center Of USC
Los Angeles, California
Cedars-Sinai Medical Center
Los Angeles, California
UCLA Kidney Transplant Research Program
Los Angeles, California
University of California Davis Medical Center
Sacramento, California
California Institute of Renal Research
San Diego, California
North America Research Institute
San Dimas, California
California Pacific Medical Center
San Francisco, California
Kaiser Permanente
San Francisco, California
University of California, San Francisco Medical Center
San Francisco, California
University Of Colorado Hospital - Anschutz Medical Campus
Aurora, Colorado
Tampa General Medical Group
Tampa, Florida
Northwestern Memorial Hospital
Chicago, Illinois
Rush University Medical Center - University Cardiovascular Surgeons
Chicago, Illinois
Indiana University (IU) Health Physicians - Kidney Diseases Clinic - Medical Diagnostic Center Location
Indianapolis, Indiana
Unity Point Health
Des Moines, Iowa
Holden Comprehensive Cancer Center, University of Iowa Hospitals and Clinics
Iowa City, Iowa
University of Louisville Research Foundation
Louisville, Kentucky
Tulane University Health Sciences Center
New Orleans, Louisiana
Massachusetts General Cancer Center
Boston, Massachusetts
Beth Israel Deaconess Medical Center
Boston, Massachusetts
Henry Ford Health System
Detroit, Michigan
University of Minnesota
Minneapolis, Minnesota
Mayo Clinic
Rochester, Minnesota
Washington University School of Medicine - Infectious Diseases (WU ID) Clinic
St Louis, Missouri
University of Nebraska Medical Center
Omaha, Nebraska
Saint Barnabas Medical Center
Livingston, New Jersey
Erie County Medical Center Corp.
Buffalo, New York
NYU Langone Medical Center
New York, New York
New York Presbyterian Hospital / Weill Cornell Medical Center
New York, New York
Columbia University Medical Center
New York, New York
Duke Cancer Institute
Durham, North Carolina
Wake Forest University Health Sciences
Winston-Salem, North Carolina
The Ohio State University, Comprehensive Transplant Center
Columbus, Ohio
University of Cincinnati
Toledo, Ohio
Integris Baptist Medical Center
Oklahoma City, Oklahoma
Lehigh Valley Health Network
Allentown, Pennsylvania
Central Pennsylvania Transplant Foundation
Harrisburg, Pennsylvania
University of Pennsylvania
Philadelphia, Pennsylvania
Showing 40 of 142 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.